From Laboratory Research to Commercial-scale Production
What Does It Take to Industrialize Synthetic Biology?
Download the Whitepaper
Industrializing synthetic biology requires biological design to work in step with process equipment, production platforms, pilot-scale validation, and end-use applications. Policy, regulation, financing, and innovation systems also influence how this transition unfolds across markets.
Frost & Sullivan’s latest whitepaper, Global and China Synthetic Biology and Biomanufacturing Industry Development, examines this path across the value chain and the approaches taken by companies such as Ginkgo Bioworks, Beam Therapeutics, C3 Biotech, and bit.bio.
Key Takeaways from Frost & Sullivan’s Latest Whitepaper
Follow the industry chain from raw materials, process equipment, and chassis cells to platform technologies and products serving biomedicine, consumer goods, agriculture, advanced materials, energy, and environmental protection.
Explore developments in gene sequencing, gene editing, gene synthesis, metabolic engineering, multi-omics, systems biology, bioinformatics, and AI. Understand the role of these technologies in biological research and process development.
Review the policy, regulatory, financing, and innovation environments in China, the United States, the European Union, and the United Kingdom. See how the conditions supporting industry development differ across these economies.